Antibodies News and Research

RSS

To quarantine or not: The hard choices schools are leaving to parents and staff

On the second day of high school in Texas, Natosha Daniels' 14-year-old daughter went all day without eating because she did not want to remove her mask.

1 Sep 2021

New candidate vaccine for COVID-19 found to be efficacious in preclinical models

More than a year after the start of the COVID-19 pandemic, several vaccines have been authorized thanks to unprecedented worldwide research efforts. These first-generation vaccines bring great hope and are a mainstay in fighting the virus.

1 Sep 2021

New review looks at the bottlenecks and breakthroughs in cancer immunotherapy

After over a century of development, cancer immunotherapy (CIT) has risen to become a promising approach for treating cancer. Unlike conventional methods that try to kill cancer cells directly, CIT involves modifying or stimulating the immune system's natural ability to fight the disease. So far, various CIT treatments have shown remarkable results in terms of survival rates, and many new and combination strategies are currently under study.

1 Sep 2021

Increased transmissibility drives SARS-CoV-2 variant spread, aided by immune escape

Numerous variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged over the last few months. Unfortunately, this has driven new coronavirus disease 2019 (COVID-19) waves, often more severe than before. A recent study posted to the medRxiv* preprint server discusses the characteristics of the variant that is responsible for this phenomenon.

31 Aug 2021

Attenuated virulence and protective immunity in SARS-CoV-2 with a mutation in the S1/S2 cleavage site

A new study published in mBio investigates the impact of the furin cleavage site on viral growth and pathogenesis.

31 Aug 2021

Development of SARS-CoV-2 antibody escape variants in an immunocompromised individual

A new study published in mBio discusses the microevolution of SARS-CoV-2.

31 Aug 2021

Does SARS-CoV-2 infection protect against reinfection?

A new review showed that the protective effect of prior SARS-CoV-2 infection is at least equivalent to that of vaccination.

31 Aug 2021

Researchers identify biomarkers for rare, serious complication in children with COVID-19

The study focused on multisystem inflammatory syndrome in children (MIS-C), an inflammatory response involving multiple organs that can occur weeks after infection with SARS-CoV-2, the virus that causes COVID-19.

31 Aug 2021

$1.3 million in NIH funding to enable drug delivery technology research

Two National Institute of Health grants totaling over $1.3 million will enable research into antibody-mediated drug delivery technology for the treatment of cancer and autoimmune disorders. L. Nathan Tumey, assistant professor of pharmaceutical sciences at Binghamton University, State University of New York, is the Principal Investigator on both grants - $1.2 million from the National Institute of General Medical Sciences and $150,000 from the National Institute of Allergy and Infectious Diseases.

31 Aug 2021

mRNA COVID-19 vaccines induce high antibody titers with significant neutralizing potency in saliva

Scientists from the USA and Canada have recently demonstrated that the dynamics of antibody response induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) vaccines are different.

31 Aug 2021

Post-infection vaccination produces potent neutralizing antibodies against SARS-CoV-2 variants

The best protection against new SARS-CoV-2 infections or reinfections may be obtained by a combination of vaccine-elicited and infection-induced antibodies.

31 Aug 2021

J&J COVID-19 booster shot produces robust antibody response

The study showed neutralizing antibody responses produced by the Johnson & Johnson–Janssen vaccine was robust and stable eight months after immunization.

31 Aug 2021

The tale of mRNA vaccines: Turning calamity into opportunity

In a review paper published in the journal Nature Reviews, researchers from Carnegie Mellon University and the University of Pennsylvania have described the underlying technologies for mRNA vaccines and their future prospects with improved delivery systems and applications in diseases beyond the ongoing COVID-19 pandemic.

31 Aug 2021

Shorter survival of multiple myeloma subgroup linked to worse kidney damage

Nearly 20% of patients with multiple myeloma have a form in which they make extreme quantities of one component of the abnormal antibody they are producing, and these so-called "free monoclonal light chains" pile up and damage the kidneys, investigators say.

31 Aug 2021

Durability of cellular immune memory to SARS-CoV-2 after mRNA vaccination

A recent study, available on the bioRxiv* preprint server, investigated the durability of cellular immune memory after mRNA vaccination against SARS-CoV-2 and whether booster jabs affect the durability of different immune response components. The study included testing for antibodies and cellular immune responses in covid patients and recovered individuals.

31 Aug 2021

Monoclonal antibody treatment combo can reduce the impact of COVID-19 in high-risk patients

In an observational study, Mayo Clinic researchers report that the combination of casirivimab and imdevimab - two monoclonal antibody treatments under Food and Drug Administration emergency use authorization - keep high-risk patients out of the hospital when infected with mild to moderate COVID-19. The findings appear in The Lancet's EClinicalMedicine.

31 Aug 2021

Scientists identify potential biomarkers to predict COVID-19 outcomes

A team of scientists from the United States has recently examined the trajectory of early immune biomarkers in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. They have identified specific plasma proteins that can accurately predict the clinical and virological outcomes in SARS-CoV-2 infected patients. The study is currently available on the medRxiv* preprint server.

31 Aug 2021

COVID-19 vaccine elicits antibody responses in nearly 9 out of 10 people taking immunosuppressants

COVID-19 vaccination elicited antibody responses in nearly nine out of 10 people with weakened immune systems, although their responses were only about one-third as strong as those mounted by healthy people, according to a study by researchers at Washington University School of Medicine in St. Louis.

30 Aug 2021

Prevalence of vaccine breakthrough cases in SF Bay Area

A new study focuse on studying breakthrough infections in a highly vaccinated community owing to the emergence of SARS-CoV-2 variants.

30 Aug 2021

Will mRNA vaccine boosters be required for SARS-CoV-2 variants?

A new study shows that the highly effective mRNA Moderna vaccine designed against the original SARS-CoV-2 strain may lose some efficacy as new variants arise.

30 Aug 2021

Antibodies News and Research

To quarantine or not: The hard choices schools are leaving to parents and staff

New candidate vaccine for COVID-19 found to be efficacious in preclinical models

New review looks at the bottlenecks and breakthroughs in cancer immunotherapy

Increased transmissibility drives SARS-CoV-2 variant spread, aided by immune escape

Attenuated virulence and protective immunity in SARS-CoV-2 with a mutation in the S1/S2 cleavage site

Development of SARS-CoV-2 antibody escape variants in an immunocompromised individual

Does SARS-CoV-2 infection protect against reinfection?

Researchers identify biomarkers for rare, serious complication in children with COVID-19

$1.3 million in NIH funding to enable drug delivery technology research

mRNA COVID-19 vaccines induce high antibody titers with significant neutralizing potency in saliva

Post-infection vaccination produces potent neutralizing antibodies against SARS-CoV-2 variants

J&J COVID-19 booster shot produces robust antibody response

The tale of mRNA vaccines: Turning calamity into opportunity

Shorter survival of multiple myeloma subgroup linked to worse kidney damage

Durability of cellular immune memory to SARS-CoV-2 after mRNA vaccination

Monoclonal antibody treatment combo can reduce the impact of COVID-19 in high-risk patients

Scientists identify potential biomarkers to predict COVID-19 outcomes

COVID-19 vaccine elicits antibody responses in nearly 9 out of 10 people taking immunosuppressants

Prevalence of vaccine breakthrough cases in SF Bay Area

Will mRNA vaccine boosters be required for SARS-CoV-2 variants?

How to make hybridoma-based antibody discovery more efficient eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo